-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Erythropoietin using targeted increase in hemoglobin levels to treat anemia in patients with chronic kidney disease and its heart vessels increased risks associated, including stroke risk
Heart vascular stroke
Recently, a research article was published in JAHA, an authoritative journal in the field of cardiovascular disease.
Researchers used the Cox proportional hazards regression model to estimate the risk ratio (HR) of stroke and its subtypes in erythropoietin-treated patients compared to non-treated patients
Odds ratio analysis result
Compared with non-erythropoietin users, the risk of stroke in erythropoietin users did not increase (adjusted HR 1.
It can be seen that the use of erythropoietin therapy in patients undergoing hemodialysis has nothing to do with the increased risk of stroke or any subtype of stroke
Erythropoietin therapy in patients on hemodialysis is not associated with an increased risk of stroke or any of its subtypes of stroke
Original source:
Original source:Peir‐Haur Hung.
Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan
in this message